



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

AUG 12 1999

Mr. Earnie S. Philpot
President
Therasys, Incorporated
2295 North Moraine Drive
Moraine, Ohio 45439

Re: K991931
Trade Name: CTD Mark I Traction Device
Regulatory Class: II
Product Code: ITH
Dated: June 3, 1999
Received: June 8, 1999

Dear Mr. Philpot:

We have reviewed your Section 510(k) notification of intent to market the device referenced above, and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general control provisions of the Act. The general control provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895.

A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General Regulation (21 CFR Part 820), and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

A handwritten signature in black ink, appearing to read "C. Witten", with a stylized flourish at the end.

Celia M. Witten, Ph.D., M.D.

Director

Division of General and
Restorative Devices

Office of Device Evaluation

Center for Devices and
Radiological Health

Enclosure

1C991931/A

Food and Drug Administration

June 22, 1999


DUPLICATE

510K Number: K991931

Device Name: CTD MARK I TRACTION DEVICE

INDICATIONS FOR USE:

The CTD Mark I is a mobile, cervical, pneumatic **pulling-traction device** expressly used to perform traction and mobilization of the cervical muscles and vertebrae. It provides intermittent or continuous traction modes. The CTD Mark I when used as a cervical traction device is for clinical use only by prescription of a licensed physician.


(Division Sign Off)
Division of General Restorative Devices
510(k) Number K991931

Prescription Use X
(Per 21 CFR 801.109)